Loading cancer entity…
Loading cancer entity…
Clinical trials
4,033 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (699)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06268574 | Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML(RIVER-52) | terminated | Phase 2 | 62 | Ryvu Therapeutics SAINDUSTRY | 4 | Sep 16, 2026 | clinicaltrials |
| NCT06397313 | RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis(POTAMI-61) | terminated | Phase 2 | 36 | Ryvu Therapeutics SAINDUSTRY | 2 | Sep 16, 2026 |
| clinicaltrials |
| NCT06704152 | BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS | terminated | Phase 1 / Phase 2 | 2 | BlueSphere Bio, IncINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04010877 | Multiple CAR-T Cell Therapy Targeting AML | terminated | Phase 1 / Phase 2 | 10 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05780879 | A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia | terminated | Phase 2 | 10 | University of Michigan Rogel Cancer CenterOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT02392572 | ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome | terminated | Phase 1 / Phase 2 | 58 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04994808 | Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia | terminated | Phase 2 | 23 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT03874858 | A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia(DANTE) | terminated | Phase 2 | 135 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT03146871 | Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent | terminated | Phase 2 | 7 | University of Southern CaliforniaOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT04550442 | Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | terminated | Phase 1 / Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04824794 | GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies | terminated | Phase 1 / Phase 2 | 130 | GenmabINDUSTRY | 20 | May 19, 2026 | clinicaltrials |
| NCT03246906 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation | terminated | Phase 2 | 150 | Fred Hutchinson Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT02629692 | Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies | terminated | Phase 1 / Phase 2 | 124 | Sun Pharma Advanced Research Company LimitedINDUSTRY | 10 | May 13, 2026 | clinicaltrials |
| NCT04639024 | ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN | terminated | Phase 2 | 3 | Gwynn Long, M.D.OTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT03878199 | Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms | terminated | Phase 1 / Phase 2 | 12 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT04435691 | Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 110 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03150004 | Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) | terminated | Phase 2 | 53 | Medical College of WisconsinOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06563804 | A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML | terminated | Phase 1 / Phase 2 | 13 | Servier Bio-Innovation LLCINDUSTRY | 6 | Mar 30, 2026 | clinicaltrials |
| NCT03922100 | Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML | terminated | Phase 1 / Phase 2 | 63 | Nerviano Medical SciencesINDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT04347616 | Natural Killer-cell Therapy for Acute Myeloid Leukemia(NK4AML) | terminated | Phase 1 / Phase 2 | 9 | Radboud University Medical CenterOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT03404193 | Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome | terminated | Phase 2 | 235 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04216563 | ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor | terminated | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT04160052 | Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome | terminated | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT04150029 | A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy(STIMULUS-AML1) | terminated | Phase 2 | 90 | Novartis PharmaceuticalsINDUSTRY | 10 | Jan 13, 2026 | clinicaltrials |
| NCT05799079 | Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant | terminated | Phase 2 | 1 | Sanjay MohanOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04240002 | A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | terminated | Phase 1 / Phase 2 | 9 | Astellas Pharma Global Development, Inc.INDUSTRY | 5 | Jan 5, 2026 | clinicaltrials |
| NCT03055286 | Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients | terminated | Phase 1 / Phase 2 | 15 | JW PharmaceuticalINDUSTRY | 2 | Dec 26, 2025 | clinicaltrials |
| NCT05361057 | Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients | terminated | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT00776373 | Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies(UPCC 25406) | terminated | Phase 1 / Phase 2 | 4 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT04874194 | Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 | terminated | Phase 1 / Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT04511130 | Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant(ARTEMIS) | terminated | Phase 2 | 92 | Marker Therapeutics, Inc.INDUSTRY | 1 | Oct 30, 2025 | clinicaltrials |
| NCT00726232 | Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia | terminated | Phase 2 | 73 | Incyte CorporationINDUSTRY | 2 | Oct 29, 2025 | clinicaltrials |
| NCT04623216 | Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation. | terminated | Phase 1 / Phase 2 | 24 | Novartis PharmaceuticalsINDUSTRY | 4 | Oct 16, 2025 | clinicaltrials |
| NCT05358808 | ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)(ACHIEVE) | terminated | Phase 2 | 16 | TC BiopharmINDUSTRY | 1 | Sep 30, 2025 | clinicaltrials |
| NCT03860844 | Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia(ISAKIDS) | terminated | Phase 2 | 67 | SanofiINDUSTRY | 16 | Sep 9, 2025 | clinicaltrials |
| NCT02438761 | PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)(5) | terminated | Phase 2 | 10 | Institut CurieOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT03769532 | MRD-guided Treatment in NPM1mut AML Patients(PEMAZA) | terminated | Phase 2 | 26 | Technische Universität DresdenOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT06679582 | Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML | terminated | Phase 1 / Phase 2 | 24 | Sutro Biopharma, Inc.INDUSTRY | 9 | Aug 24, 2025 | clinicaltrials |
| NCT06508489 | A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies | terminated | Phase 1 / Phase 2 | 7 | SanofiINDUSTRY | 2 | Aug 22, 2025 | clinicaltrials |
| NCT03333486 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer | terminated | Phase 2 | 31 | Roswell Park Cancer InstituteOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT04103645 | Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients | terminated | Phase 2 | 2 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT03724084 | Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement | terminated | Phase 1 / Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Jun 18, 2025 | clinicaltrials |
| NCT06449482 | Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy | terminated | Phase 1 / Phase 2 | 6 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT04752163 | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT03537599 | Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 4 | Sumithira VasuOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT05447663 | A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 8 | Novartis PharmaceuticalsINDUSTRY | 3 | May 16, 2025 | clinicaltrials |
| NCT03576547 | Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia | terminated | Phase 1 / Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT01532635 | A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives | terminated | Phase 2 | 4 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT03615105 | Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors | terminated | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT03686345 | Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia(AML FLT3) | terminated | Phase 2 | 34 | Niguarda HospitalOTHER | 1 | Feb 25, 2025 | clinicaltrials |
Data updated 13 days agoSource updated Sep 16, 2026source: clinicaltrials